(Q43238309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Noriko Nakura

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Stephanie Le Breton

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Deborah Keefe

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

20 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

published in

Hypertension Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

62-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

Global burden of hypertension: analysis of worldwide data

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Renal protection and antihypertensive drugs: current status

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Current status of antihypertensive prescription and associated blood pressure control in Japan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Nephroprotective effect of antihypertensive drugs in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Blood pressure control and nephroprotection in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.175

7 January 2021

Identifiers

DOI

10.1038/HR.2009.175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19927154%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference